Liver Cancer Trial, Recruiting (NCT07169656)

Liver Cancer Trial, Recruiting NCT07169656 Sponsor: The First Affiliated Hospital of Zhengzhou University Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07169656 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have had a chronic hepatitis B infection for 6 months or more (confirmed by a positive HBsAg test)
People aged 18 years or older
People who are currently receiving, or are planned to receive, one of the following hepatitis B treatments in routine clinical care: Entecavir (ETV), Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide fumarate (TAF), or Tenofovir amibufenamide (TMF)
People who have never previously received pegylated interferon α-2b treatment, or who are restarting pegylated interferon α-2b therapy after a break
People who have given written consent to participate

Who may not be able to join:

People with severe liver problems or advanced cirrhosis where the liver is no longer functioning adequately
People who are already taking part in another clinical trial
People who have been diagnosed with liver cancer (hepatocellular carcinoma)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hongxia Liang, The First Affiliated Hospital of Zhengzhou University

Phone: 18595871806

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07169656

Sponsor: The First Affiliated Hospital of Zhengzhou University

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

Trial contact: 18595871806

More information: https://clinicaltrials.gov/study/NCT07169656

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have had a chronic hepatitis B infection for 6 months or more (confirmed by a positive HBsAg test)
People aged 18 years or older
People who are currently receiving, or are planned to receive, one of the following hepatitis B treatments in routine clinical care: Entecavir (ETV), Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide fumarate (TAF), or Tenofovir amibufenamide (TMF)
People who have never previously received pegylated interferon α-2b treatment, or who are restarting pegylated interferon α-2b therapy after a break
People who have given written consent to participate

Who may not be able to join:

People with severe liver problems or advanced cirrhosis where the liver is no longer functioning adequately
People who are already taking part in another clinical trial
People who have been diagnosed with liver cancer (hepatocellular carcinoma)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The First Affiliated Hospital of Zhengzhou University

Registry

ClinicalTrials.gov

Start date

3 June 2024

Est. completion

30 June 2032

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of patients with HBsAg-associated HCC post-therapy; Hepatocellular Carcinoma (HCC) Incidence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov